Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acrivon TherapeuticsACRV +3.20%35 Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2026. GuruFocus rates ACRV with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 1,336 Biotechnology companies, Acrivon Therapeutics ranks worse than 74850.22% on this metric.
Acrivon Therapeutics's Enterprise Value for the quarter that ended in Jun. 2026 was $0.00 Mil.
Acrivon Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was $-78.37 Mil. Acrivon Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 0.00%.
The historical rank and industry rank for Acrivon Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
ACRV'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 0 Med: 0 Max: 714.29
Current: 714.29
During the past 6 years, the highest Earnings Yield (Joel Greenblatt) of Acrivon Therapeutics was 714.29%. The lowest was 0.00%. And the median was 0.00%.
ACRV's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -10.135
vs ACRV: 714.29
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Acrivon Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Acrivon Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms
Acrivon Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Acrivon Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acrivon Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acrivon Therapeutics Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Acrivon Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Acrivon Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Acrivon Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Acrivon Therapeutics's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-78.37 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
Acrivon Therapeutics (ACRV) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Acrivon Therapeutics and its competitors. According to the industry distribution chart, Acrivon Therapeutics ranks #999999 out of 1336 companies in the Biotechnology industry.
Is Acrivon Therapeutics' Earnings Yield (Joel Greenblatt) % too high?
Acrivon Therapeutics' current Earnings Yield (Joel Greenblatt) % is 0.00%. Based on the distribution chart, Acrivon Therapeutics ranks #999999 out of 1336 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Acrivon Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Acrivon Therapeutics' Earnings Yield (Joel Greenblatt) % compare to SPRO and BSEM?
According to the Biotechnology industry distribution chart, Acrivon Therapeutics ranks #999999 out of 1336 companies for Earnings Yield (Joel Greenblatt) %. This places Acrivon Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Acrivon Therapeutics and its competitors. Acrivon Therapeutics's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acrivon Therapeutics stock overvalued right now?
Acrivon Therapeutics (ACRV) has a current Earnings Yield (Joel Greenblatt) % of 0.00%. The current Earnings Yield (Joel Greenblatt) % is 0.00%. Acrivon Therapeutics' overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Acrivon Therapeutics (ACRV), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1; ACR-2316 a selective, dual WEE1/PKMYT1 inhibitor; and ACR-6840, a development candidate targeting CDK11. It has one reportable segment focused on the research and development of precision oncology therapies.
35GF Score
Get the complete analysis for ACRV
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACRV has been successfully added to your 
